Lerodalcibep licensing deal, growth in the US portfolio and tariff relief offer triggers, while the proposed Organon acquisition could broaden its global reach
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.